Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Allergology : what's new in 2024].
Rev Med Suisse
January 2025
Service d'immunologie et d'allergologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
In recent years, studies have focused on the in vitro diagnosis of immediate drug reactions, with new recommendations concerning the use of the basophil activation test. Air pollution, particularly fine particles with a diameter of less than or equal to 2.5 m (PM2.
View Article and Find Full Text PDFHome-use agents in the treatment of dentin hypersensitivity: clinical effectiveness evaluation with different measurement methods.
Clin Oral Investig
January 2025
Faculty of Dentistry, Department of Restorative Dentistry, Çanakkale Onsekiz Mart University, Çanakkale, 17100, Turkey.
Objectives: This study aimed to evaluate the effectiveness of home-use desensitizing agents over an 8-week period by comparing them using different measurement methods.
Methods: A randomized, controlled clinical trial was conducted with 180 individuals aged between 18 and 70 who clinically diagnosed dentin hypersensitivity (DH) in two or more non-adjacent teeth. Subjects who met the inclusion criteria (n = 164) were randomly allocated into five test groups-using Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP), Arginine, Novamin, Propolis, and Potassium nitrate-and a control group using standard fluoride toothpaste.
Oral vancomycin induced flushing syndrome in a multiple myeloma patient: A case report and review of the literature.
Medicine (Baltimore)
November 2024
Department of Clinical Pharmacy, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background: Patients with hematological malignancies are at high-risk of Clostridium difficile infection (CDI). Oral vancomycin is a first-line treatment for CDI. Vancomycin has been widely reported to induce flushing syndrome (also known as Red man syndrome), a well-known hypersensitivity reaction mostly occurs after intravenous administration.
View Article and Find Full Text PDFThe combination of Qing Kailing injection and clindamycin injection leads to systemic adverse reactions: Case report.
Medicine (Baltimore)
November 2024
Department of Pharmacy, Baiyin Central Hospital, Baiyin, Gansu, China.
Rationale: It is imperative to be cautious about the potential systemic allergic reaction caused by the combined use of Qing Kailing Injection (QKI) and clindamycin as it may be life-threatening.
Patient Concerns: A 48-year-old female with a history of hypertension was admitted to a private hospital with a fever and cough. She was diagnosed with lung infection and received QKI infusion, followed by clindamycin infusion.
Erlotinib-induced Perioral Lesions Resembling Scleroderma.
Acta Dermatovenerol Croat
November 2024
Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!